16.04.2015 • Topics • capabilities • GE • GE Healthcare

Rentschler Expands European Manufacturing Capabilities with GE Bioprocess Technologies

GE Healthcare Life Sciences has handed over its 1000th ÄKTAprocess to Rentschler Biotechnologie for use in the expanded biopharmaceutical manufacturing capabilities Rentschler has established in Laupheim, Germany.

The equipment supplied by GE features an automated process and manufacturing scale chromatography system. The offshoot of the US conglomerate said its biomanufacturing technologies such as the XDR 2000L bioreactor, the associated seed trains of 50, 200 and 500 L as well as the new ÄKTAprocess all play a key role in Rentschler's new single-use manufacturing line.

Peter Rogge, vice president of USP Production at Rentschler, said the new line "will further enhance our ability to deliver high quality projects for companies around the globe," adding that the GE technology is also enabling an increase in Europe of next-generation manufacturing capabilities.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.